tag:blogger.com,1999:blog-3727160219530426882008-02-02T22:05:52.557-08:00DNAmitenoreply@blogger.comBlogger2125tag:blogger.com,1999:blog-372716021953042688.post-90780520134769124842008-01-29T13:11:00.000-08:002008-01-29T13:34:54.864-08:00One interesting startup company I came across is Aureon, which developed a biomarker diagnostic, which predicts PSA recurrence and clinical disease progression in patients who have undergone radical prostatectomy. Samples are collected using needle biopsy.<br /><br />The first diagnostic is Prostate Px, which looks at a set of seven protein prostate cancer biomarkers to fairly accurately predict PSA recurrence.<br /><br />Among Aureon's founders are leading scientists at Memorial Sloan-Kettering Cancer Center, Yale Cancer Center, and Albert Einstein College of Medicine. he company is well financed and is rapidly moving ahead with its proastata diagnostic.<br /><br />ww.aureon.comDNAmitenoreply@blogger.comtag:blogger.com,1999:blog-372716021953042688.post-29559702028731771222008-01-18T20:05:00.000-08:002008-01-18T20:14:35.557-08:00I attended <a href="http://www.gtcbio.com">GTCbio's</a> Oncology Biomarkers conference held in San Francisco's hotel Whitcomb last week. The <a href="http://www.biotechnologymeetings.com">biotech calendar </a>has many biomarker conferences this year, but this event was definitely one of the best out there.<br /><br />The level of delegates was striking and presentations were top notch!DNAmitenoreply@blogger.com